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• Endometrial cancer (EC) is under-researched and there are many knowledge gaps.
• We used James Lind Alliance methodology to prioritise unanswered research questions in EC.
• The top 10 questions span EC risk prediction, diagnosis, treatment and survivorship.
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Available online 1 September 2016Background. Endometrial cancer (EC) is themost common gynaecological cancer in developed nations and its
incidence is rising. As a direct consequence, more women are dying from EC despite advances in care and im-
proved survivorship. There is a lack of research activity and funding, as well as public awareness about EC. We
sought to engage patients, carers and healthcare professionals to identify the most important unanswered re-
search questions in EC.
Methodology. The priority setting methodology was developed by the James Lind Alliance and involved four
key stages: gathering research questions; checking these against existing evidence; interim prioritisation; and a
ﬁnal consensus meeting during which the top ten unanswered research questions were agreed using modiﬁed
nominal group methodology.
Results. Our ﬁrst online survey yielded 786 individual submissions from 413 respondents, of whom211were
EC survivors or carers, and fromwhich 202 unique unanswered research questionswere generated. 253 individ-
uals, including 108 EC survivors and carers, completed an online interim prioritisation survey. The resulting top
30 questionswere ranked in a ﬁnal consensusmeeting. Our top ten spanned the breadth of patient experience of
this disease and included developing personalised risk scoring, reﬁning criteria for specialist referral, understand-
ing the underlying biology of different types of EC, developing novel personalised treatment and prevention
strategies, prognostic and predictive biomarkers, increasing public awareness and interventions for psychologi-
cal issues.
Conclusion.Having established the top ten unanswered research questions in EC, we hope this galvanises re-
searchers, healthcare professionals and the public to collaborate, coordinate and invest in research to improve the
lives of women affected by EC.
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Endometrial cancer (EC) is now the most common gynaecological
malignancy in developed nations [1]. In the UK, age standardised inci-
dence rates have increased by 25% in the last decade [2]. Although this
trend has not been mirrored in the US where the age standardised
rate of EC has remained stable, the latter statistic masks the rise in the
absolute numbers of women being diagnosed with this condition. In
2016, 60,050 women will be diagnosed with EC in the US [3]. By 2030,
this is expected to double to 122,000 cases, overtaking lung and colorec-
tal cancer to become the thirdmost common cancer affectingwomen in
the US [4]. These trends can in large part be attributed to the increase in
overweight and obesity and demographic shifts which mean that a
greater proportion of our population is now over 65 [5]. These statistics
also serve to mask the disproportionate increase in disease burden
amongst minority populations. Black and Hispanic women have seen a
2.4% and 4.4% age-adjusted increase in EC incidence respectively [3].
The age standardised mortality rate for British women with EC has
increased alongside incidence over the last decade [6]. Based on current
data extrapolated from trends in the US, by 2030 this couldmean an ad-
ditional 30–40,000 deaths per year worldwide [4]. There is an urgent
need to curb the escalating burden of EC through risk prediction and
targeted prevention strategies. Since the majority of women are diag-
nosed with early stage disease and cured by hysterectomy, reducing
the physical burden of treatment and addressing the psychological
after-effects for survivors is also important.
Low public awareness of the disease [7,8] has been accompanied by
a lack of interest amongst grant-awarding bodies and leading
gynaecological oncology researchers. This is reﬂected in a smaller
share of research funding than is warranted by the rising incidence
and mortality; 0.7% (£3.3 million) of the UK's total budget [9] and
one-ﬁfth of that allocated to ovarian cancer research in 2012. This is
mirrored in the US, where $17.8 million was allocated to EC research
in 2013 by the National Cancer Institute compared to $100.6 million to
ovarian cancer research [10]. Although some important practice chang-
ing evidence exists in surgery and radiotherapy, chronic underfunding
compared to other cancers has meant that there are many knowledge
gaps. In particular, there is a growing need to discover equitable, effec-
tive and cost-effective interventions to improve the prevention, detec-
tion and treatment of EC.
Traditionally, medical research questions have been developed and
funded following academic peer review with minimal input from po-
tential users of the research i.e. patients, carers and non-research active
healthcare professionals. This model has been criticised aswasteful [11]
and there are frequently considerable mismatches between the priori-
ties of researchers and patients [12]. More recently, the advantages of
involving patients and healthcare professionals in the identiﬁcation of
research priorities have been recognised [13]. This ensures the right
questions are asked and that potential solutions are acceptable to
patients. Major funders nowmandate active patient and public involve-
ment in the design and execution of the research they fund. To support
this process, the James Lind Alliance (JLA) was established in 2004 to
bring together patients, carers and clinicians to identify shared research
priorities in various healthcare ﬁelds. The JLA advocates the develop-
ment of consensus about research priorities through a series of surveys,
stakeholder meetings and guided discussions. This approach provides a
systematic, explicit and transparent process through which future
health research can be commissioned.
The aim of this study was to engage EC survivors, carers and
healthcare professionals in a dialogue to establish a consensus regarding
the top ten unanswered research questions in EC.
2. Methodology
This study followed the JLApriority settingmethod [14]. This process
is set out to ensure consistency between priority setting partnershipsand has been used to prioritise research priorities in over 60 healthcare
ﬁelds [15]. Key stages in the process are described below.
2.1. Establishing a steering group
In 2014, we established the Womb Cancer Alliance to identify the
most important unanswered research questions in EC through a
broad-based consultative process. As part of the JLA process, all organi-
sations that could reach and advocate for patients, carers and clinicians
were invited to become involved in a Priority Setting Partnership (PSP).
A steering group composed of representatives from these groups was
then formed to ensure the study remained inclusive and fulﬁlled its
aim to deliver and publicise a list of shared research priorities. This
steering group was established from a purposive sample of individuals
with patient experience of EC and healthcare professionals from prima-
ry care, obstetrics and gynaecology, gynaecological oncology, clinical/
medical oncology, gynaecological cancer specialist nursing, as well as
representatives from women's health and cancer charities. Groups
with signiﬁcant competing interests such as pharmaceutical companies
were excluded. By employing a maximum variation approach in the se-
lection ofmembers to this steering group, we hoped tomaximise the di-
versity of its frames of reference. An independent advisor from the
James Lind Alliance was Chair of the steering group. This ensured that
conﬂicts of interest were minimised.
Partner organisations that supported the alliance included the Brit-
ish Gynaecological Cancer Society, Macmillan Cancer Voices, National
Forum of Gynaecological Oncology Nurses, James Lind Alliance (JLA),
Womb Cancer Support UK, Womb Cancer Voice, Eve Appeal, Wellbeing
of Women, Cochrane, National Institute of Health Research, Pelvic Ob-
stetric and Gynaecological Physiotherapists, College of Radiographers
and Allied Health Professionals Network.
2.2. The consultative process
The University of Manchester Research Ethics Committee 3
(ref. 14435) approved the study. The initial consultative phase formed
the ﬁrst part of a modiﬁed Delphi consensus making approach [16]
whereby individuals were invited to provide their opinion through an
anonymised survey. A website was created (http://research.bmh.
manchester.ac.uk/wombcanceralliance) to advertise the initiative and
link to the online survey. Prospective participantswere invited to engage
with the consultation process by advertisements sent through mailing
lists of the stakeholder groups, social media and by national and local
press releases. EC survivors were recruited from online peer support fo-
rums and informal networks supported by Womb Cancer Alliance pa-
tient partners and by direct invitation if enrolled in current ongoing
clinical trials. Carers with an interest in ECwere recruited through social
media initiatives. Healthcare professionals on mailing lists of Womb
Cancer Alliance partner organisations were sent electronic invitations.
2.3. Gathering uncertainties
The initial consultation was performed via an electronic question-
naire, which was also available on paper at request. Submissions were
accepted between 23rd March 2015 and 31st May 2015. Non-probabil-
ity sampling methods were used to maximise the diversity of opinions
offered. In line with the aims of the JLA approach, this promoted inclu-
sivity of all patients and professionals who might wish to contribute to
the study. Sociodemographic data of the participants were monitored
throughout the data gathering period and where particular groups
appeared under-represented, targeted recruitment strategies were
employed. These included providing paper copies of the survey with a
self-addressed envelope for return of the completed questionnaire to el-
derly participantswhowere not comfortable submitting their questions
online. Participants were asked ‘What are the most important research
questions in womb cancer?’ and were provided with examples of
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gathered from current EC guidelines from Europe and North America.
2.4. Data analysis and verifying uncertainties
Entries were grouped into themes. Each themewas analysed by two
members of the steering group, one with patient experience of EC and
the other a healthcare professional with an interest in this area; thus 7
pairs of reviewers contributed to the analysis of the dataset. This ensured
that the exclusion of entries was less likely to be affected by researcher
bias given the diversity of expertise amongst the steering group. Tomax-
imise the reproducibility of categorisation between reviewers, explicit
criteria of how to categorise each entry were provided a priori. When
both reviewers identiﬁed questions as duplicates, unanswerable by re-
search, out of scope or personal stories rather than research questions,
they were removed. Discrepancies were settled by independent review
by two further reviewers. Every question was searched against existing
literature and those that had already been answered by research were
removed. Literature searches were performed by an independent team
of health information specialists from the CentralManchester University
Hospitals Foundation Trust and The Christie NHS Foundation Trust using
systematic pre-agreed search criteria. Analysis of search results was per-
formed by 3 clinical researchers from the study group. Searches deemed
answered by researchwere deﬁned as thosewith recent level 1 evidence
[17] (systematic review with 3 years), where the review did not con-
clude that there was insufﬁcient evidence.
2.5. Interim priority setting
Unanswered questions that had been asked by at least three
independent participants were automatically taken forward to theFig. 1. Study ﬂow diagram showing the number oprioritisation survey. It was agreed by the steering group that using
this cut-off ensured that those questions asked the most frequently
would be reﬂected in the second Delphi survey, irrespective of whether
members of the steering group agreedwith these opinions. Those asked
less frequently were reviewed by the Womb Cancer Alliance steering
group; questions that were ‘shared’ priorities, being asked by both pa-
tients and healthcare professionals, and those viewed as fundamentally
important to improving EC care were also taken forward to the second
survey which constituted the ranking phase of the modiﬁed Delphi
technique. Between 19th October 2015 and 26th November 2015, the
second online survey asked patients and healthcare professionals to
select the two most important questions from each of 7 domains
based on the initial thematic analysis. Thesewere: aetiology/risk factors,
prevention/screening, diagnosis, primary treatment, treatment of recur-
rent disease, survivorship, and patient support issues. Each domain
contained between 8 and 10 questions. Questions were presented to
each participant in a random order to reduce bias. Participants were re-
quired tomake two selections from each domain in order to proceed to
the next stage of the survey. To ensure transparency and minimisation
of bias, this process was closely monitored by the JLA Advisor.
2.6. Final priority setting
Questions voted most or second-most important in each domain by
at least 25% of survey participants were taken forward to the ﬁnal face-
to-face consensus meeting. Volunteers from partner organisations and
individuals taking part in the online surveys were invited to attend. At-
tendees were split into three equal groups of individuals from different
professional and lay backgrounds and asked to rank the questions
through guided discussions using modiﬁed nominal group methodolo-
gy facilitated by independent JLA Advisors. These rankings weref participants and submissions at each stage.
Fig. 2. Comparison of thematic analysis between responses from (A) lay and (B)
professional participants. The submissions from the 413 respondents to the initial
survey were thematically analysed. Where respondents had offered multiple
suggestions these were analysed separately.
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ings from the small group discussions were aggregated to generate a
priority order for discussion amongst the whole group. The ﬁnal top
ten most important unanswered research questions in EC were agreed
by the full group (Fig. 1).
3. Results
3.1. Question-gathering
A total of 413 participants took part in the question-gathering sur-
vey, including 211 (51%) patients, carers and individuals who identiﬁed
themselves as being at risk of EC. Participant demographics are shown
in Table 1. The ﬁrst survey yielded 788 entries, which were grouped
into themes. Word clouds depicting the relative frequency with which
questions were proffered for each of the top ten themes are shown for
the lay and professional groups in Fig. 2. There was somemismatch be-
tween the relative importance ascribed to each theme by the two
groups.
3.2. Veriﬁcation of uncertainties
Duplicate entries, personal stories, questions that were out of scope
or unanswerable by research were removed, leaving 218 questions. A
further 29 were derived from professional guidelines from Europe and
North America. The resulting 247 questions were searched against
existing evidence. A summary of the existing evidence for each question
is given in Fig. 3 and the full search is available for download at http://
research.bmh.manchester.ac.uk/wombcanceralliance. In total, 209Table 1




Number of EC professional
participants (%)
Sex
– Female 211 (100) 130 (64)
– Male 0 69 (34)
– Prefer not to say/no answer 0 3(2)
Age
– 18–39 29(14) –a
– 40–49 47 (22) –
– 50–59 84 (40) –
– 60–69 43 (20) –
– 70–79 5 (2) –
– N79 0 –
– Prefer not to say/no answer 3 (1) –
Ethnicity
– White (any background) 204 (98) –
– Chinese 1 (0) –
– Black Caribbean 1 (0) –
– Mixed race – White & Black
Caribbean
1 (0) –
– Prefer not to say/no answer 4 (2) –
Background
– Patient 177 (83) –
– Carer 19 (10) –
– At risk individual 15 (7) –
– General practitioner – 53 (26)
– Gynae-oncology surgeon – 51 (25)
– Nurse – 24 (12)
– Allied health professional – 18 (9)
– Clinical academic – 12 (6)
– Medical/Clinical oncologist – 9 (4)
– Diagnostic specialist – 4 (2)
– Palliative care – 3 (1)
– Other – 25 (12)
– Prefer not to say/no answer – 2 (1)
a Data regarding age and ethnicity of EC professionals was not collected as it was felt
that this was unlikely to affect responses.(85%) questions were considered unanswered by current research.
Questions regarding aetiology and epidemiology were most common.
Over one third of these questions had already been answered by
research, supporting the need for better dissemination of research
ﬁndings.
3.3. Interim prioritisation
The 54 most important unanswered research questions in EC were
further prioritised through an online survey completed by 257 people,
including 113 lay participants (45%). The 30 questions that were ranked
most or secondmost important within each of the 7 domains by 25% or
more of the participants were taken forwards to the ﬁnal consensus
meeting. This cut-off balanced the need to retain as many questions as
possible to reduce the risk of excluding an important question whilst
limiting the questions to be taken forward for consideration at the
ﬁnal consensus meeting to a manageable number. Decision making re-
search has shown that increasing the number of alternatives increases
the complexity of the decision, leading to increasing conﬂict and forcing
individuals to resort to deferring decisions, choosing the default option
or failing tomake a decision altogether [18,19]. The proportion of partic-
ipants who voted each question as most important across each of the 7
domains is shown in Fig. 4.
3.4. Final prioritisation
A group of 23 stakeholders discussed the ranking of the remaining
30 questions at the ﬁnal face-to-face consensus meeting. The stake-
holders were provided with summary information regarding how
often each question had been prioritised by lay and professional partic-
ipants to help guide these discussions.
Thirteen questions were agreed as the most important unanswered
research questions (marked in Fig. 4). Six of these had signiﬁcant over-
lap andwere amalgamated to form3 composite questions. The resulting
top ten unanswered research questions in EC are shown in Fig. 5. Al-
though the stakeholders were not constrained to choosing a certain
number of questions from each domain, questions from all domains
contributed to the ﬁnal ten (see Fig. 4). The questions selected do not
only reﬂect the most frequently prioritised questions, but also reﬂect
questions where there were roughly equal proportions of lay and pro-
fessional participants who supported its prioritisation. In fact, those
questions where it was predominately prioritised by one or other
group were not prioritised in the ﬁnal ten.
Fig. 3.Distribution of evidence base for questions from each of 7 domains. Each of 247 unique questionswas searched against current literature. The frequencywithwhich questions from
each domain were submitted and the proportion within each of these which had been addressed at each level of evidence (Level 1–5 - Oxford 2011 Levels of Evidence [17]) are shown.
Those research questions where level 1 evidence was available were further subclassiﬁed into those where the conclusion showed that there was sufﬁcient evidence i.e. ‘answered’ and
those where the evidence was insufﬁcient (i.e. level 1 alone) to state that further research was required.
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This study highlights the paucity of evidence that underpins many
aspects of care of womenwith EC. Of the 247 research questions gener-
ated in this study, we found only 15% of these had been answered byFig. 4. Frequency of prioritisation of the top 30 questions in prioritisation survey according
participants as their top 2 most important in each domain is shown along with the relative p
making up the lay participants are shown in shades of green whilst the responses from grou
constitute the ﬁnal ten are indicated by the asterisks.level 1 evidence. To begin to tackle this problem, we have developed a
consensus of the top ten unanswered research questions in EC shared
by both clinicians and patients, using an inclusive decision making ap-
proach. The top ten questions span disease risk stratiﬁcation, diagnosis,
treatment, management and survivorship that cover the breadth ofto background. The frequency with which each of the 30 questions was prioritised by
roportion of each stakeholder group which made this selection. The responses of groups
ps making up the professional participants are shaded blue. Those questions selected to
Fig. 5. Final top ten unanswered research questions in EC.
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ﬁrst step to accelerating research that will maximise health beneﬁts to
women, both at risk of EC and those who have already been diagnosed
with the disease. The next steps are to secure funding for these research
areas and to disseminate the ﬁndings of this study and those resulting
from it in an attempt to address the mismatch between disease burden
and research activity.
At the forefront of both patient and clinicians' priorities is the devel-
opment of personalised risk prediction. Over 40% of EC are thought to be
preventable [20]. Risk stratiﬁcation offers the opportunity for women to
understand their underlying risk and engage in targeted risk modiﬁca-
tion and/or screening, with the aim of reducing the incidence of EC.
These aims demonstrate a shift in paradigm from a reactive to a more
proactive approach known as ‘predictive, personalised, preventative
and participatory (P4) medicine’. This focus on prevention will provide
us with the opportunity to turn the tide on the rising numbers of
women diagnosed with, and dying from, this potentially preventable
disease. Our ﬁnding that risk prediction is the most important priority
challenges the belief that societal barriers will be the most difﬁcult ob-
stacle to achieving P4 medicine [21]. The incorporation of EC within
the 100,000 Genomes Project in England [22] and the ForeCee project
[23] will provide researchers with a wealth of data to begin building al-
gorithms that are not only based on lifestyle and behaviour, but also in-
corporate genetic predisposition. The challenge going forward is to
combine this knowledge with evidence-based prevention strategies.
Coupling preventionwith earlier diagnosis may provide the best op-
portunity to save lives. Women diagnosed with early stage disease ben-
eﬁt from longer disease-speciﬁc survival and avoid the long term
complications associated with adjuvant therapy. A focus on educating
the public about early signs of disease and providing tools for primary
care physicians to better identify women with EC and pre-cancer from
within a cohort of symptomatic women represent ways in which both
earlier detection and improvements in the experience of being diag-
nosed can be achieved. The Eve Appeal National Gynaecological Cancer
survey revealed that whilst 71% women had experienced one or more
symptoms of a gynaecological cancer, 20% had dismissed these symp-
toms as normal for someone of their age [8].
For those women diagnosed with EC, the challenges lie in
personalising care and improving quality of life following treatment.
Therefore, we need to prioritise research into developing therapies
that are not only effective but also have minimal side effects, and iden-
tifying and avoiding harmful treatments in women who would other-
wise receive no beneﬁt. Additionally, recognising that a diagnosis of
EC and its treatment has psychological, as well as physical, effects will
pave the way for much needed research into interventions to improve
the psychological wellbeing of patients. More research is also neededin non-drug interventions that empowerwomen to improve their over-
all health and reduce the risk of recurrence, thus prolonging overall
survival.
In our study, the lay participants predominantly identify as white
and under 60 years old. It is notable that individuals of Asian (i.e. people
identifying as of Indian, Pakistani, Bangladeshi or other South Asian eth-
nicity) and Black ethnicity and olderwomenwhomake up a substantial
proportion of women diagnosed with EC are underrepresented. A con-
sultation process such as this will inevitably reach patients who are al-
ready engaged in lobbying and policy change. These individuals are
often youngerwomenwith rarer forms of the disease. Other researchers
have demonstrated that younger women are more likely to perceive
that their healthcare needs are inadequately met [24]. This may also ac-
count for the disproportionate number of younger women responding
to our survey. In order to ensure that views of older womenwere repre-
sented during the initial consultation phase and the ﬁnal consensus
meeting, we speciﬁcally invited several women over 65 years of age to
participate over and above those recruited from generic call out.
Although meaningful analysis of themes by age could not be con-
ducted in our study due to the small numbers in each age group, other
researchers have noted that older women in general are more con-
cerned with preventing disability rather than speciﬁc diseases, being
treated holistically and feeling validated in their relationship with
their healthcare provider [24]. Our top ten research priorities do include
research questionswhich look to prevent themorbidity associatedwith
treatment and consider psychological and lifestyle issues. Involving
older women and women of black andminority ethnicity remains difﬁ-
cult and going forward we will need to seek to ensure the involvement
of these cohorts, since they form a signiﬁcant proportion ofwomenwith
EC, in the design of any research commissioned as a result of this study.
Ultimately, the strength of this work is the involvement of a broad
base of different stakeholders throughout the decision-making process,
to developmuch needed priorities for research in this under-recognised
condition. The involvement of healthcare professionals, patients and
carers not only increases the credibility and transparency of the ﬁnal
output as has been recognised in many other prioritisation processes
[25,26] but also ensures that these priorities are relevant and feasible.
It was clear that there were disparities in the research themes proposed
by the patient and healthcare professional groups but this reﬂected
their differing experiences of EC. For the patients, risk factors, causality,
lack of public awareness and survivorship were the predominant
themes. For the healthcare professionals, risk prediction and preven-
tion, diagnostic pathways and treatment were more pertinent. The
ﬁnal prioritisation workshop enabled all contributing groups to voice
their opinions, thus shaping the order of the top ten to reﬂect these dif-
ferent, but equally important perspectives. Without such strong patient
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ness, psychological consequences or lifestyle change following treat-
ment for EC would have ranked so highly, and yet these aspects of
being diagnosed with EC and livingwith the consequences of treatment
really matter to patients. As a group, our common experience of this
condition, as both patients and healthcare professionals, is at the time
of treatment, and this is reﬂected in the large proportion of our research
priorities focusing on this aspect of care. Nonetheless, our highest prior-
ity is prevention. We recognise that this primary focus, if successfully
delivered, will save lives for potentially a smaller investment than re-
search into treatment alone [27].
Highlighting a list of top ten unanswered research questions does
not obviate the need for research in other areas. Indeed, a limitation of
agreeing the ﬁnal top ten within a much smaller group than was in-
volved in the broader consultation is the risk that the ﬁnal set of prior-
ities and their order is biased by the participants involved on the day.
This list of priorities should, therefore, serve only to focus discussion
on how limited funding could be distributed to best meet needs and
not be used as an absolute list. We hope, by sharing the remaining list
of uncertainties, researchers with areas of expertise outside this top
ten will continue to address the many other issues that affect EC pa-
tients and the healthcare professionals who care for them.
Perhaps the most important part of this process has been the
strengthening of relationships between partner organisations, patients
and clinicians. As a result, we have developed a list of core aims to be
worked on collaboratively to deliver improvements in the lives of
women who have been diagnosed with EC and those at risk.
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